1
Derived from payout historyIncome reliability
Quarterly income profile is visible
JNJ has an income profile aligned with its dividend company role. Provider data shows 4 recent payout records.
Market dataIncome framework read
Dividend CompanyNYSEUnited States
JNJ
Johnson & Johnson
Health CarePlain dividendQuarterly
Market Snapshot
US$241.00
+US$1.92 (80.31%)
NYSE
Yield
2.22%
Rate US$5.36
Next Payment
Payment date passed
Ex-date 2026-05-26
52wk Position
89.36%
-4.25% below high
Updated just now
Decision Area
Distribution and DRIP Defense
Payout history, default DRIP coverage, and price creep pressure using market data where available.
Distribution Chart
Last 12 payments
Confirmed Expected
Coverage Ratio Test
DRIP defense check
- Cash
- US$134.00
- APR
- 0.556
- Coverage
- 0.556
Rung failed. Restore immediately or rebalance the holding.
Price Creep
Defended price ceiling
- Max defended
- US$134.00
- Cushion
- -US$107.00
- Cushion %
- -44.40%
Current US$241.00Break US$134.00
Smart Recommendation
JNJ is not defended at these inputs; top up shares, lower TPR, or test alternatives.
Research Signals
Payout sustainability
Strong
1mo agoDRIP availability
Available
1mo agoTax character
Foreign income
1mo agoDistribution history
Multi-decade
1mo agoStructure complexity
Moderate
1mo agoIncome trend
Growing
1mo agoAccount suitability
RRSP / RRIF optimal
1mo agoStructure Overview
Johnson & Johnson (JNJ) is a Dividend King with over 60 consecutive years of dividend increases, now focused entirely on pharmaceutical and medical device segments following the Kenvue consumer health spin-off. The pharmaceutical focus adds pipeline risk but also higher margin potential compared to consumer-only peers.
Canadian Planning Notes
- 1JNJ's Kenvue spin-off in 2023 changed the portfolio; plan around post-spin JNJ metrics and verify the current dividend payout ratio for the reorganized pharmaceutical/medtech business.
- 2RRSP placement shelters U.S. withholding tax; TFSA and non-registered accounts incur the 15% withholding.
- 3USD denomination requires a CAD/USD conversion assumption for Canadian income planning; use quarterly dividends per share and a conservative exchange rate.
Market Facts
Market Data
A factual market, distribution, valuation, and financial snapshot for this holding.
Canadian Context
Account placement
RRSP
Canada-U.S. treaty treatment can exempt U.S. dividends from withholding tax inside RRSP or RRIF accounts. TFSAs do not receive the same treaty treatment.
Non-registered: Foreign tax credit may be available for U.S. withholding tax.
Eligible dividend tax credit
- Total credit
- $345.27
- Effective rate
- 34.53%
Broker DRIP status
Questrade
Available
Wealthsimple
Plan-only
RBC Direct Investing
Available
TD Direct Investing
Available
U.S.-listed holdings can have withholding tax differences by account type. RRSP treatment is often more favorable than TFSA treatment.
Run Your Numbers
Carry this holding into a calculator
Use a planning tool that matches this holding's structure, payout timing, and income use case.
Related Holdings
This profile is informational only and does not constitute licensed financial advice. Signal values, planning notes, market data, and structure summaries may not reflect the most current issuer disclosures. Always verify current payout policy, ex-dividend dates, financial statements, and issuer communications before making any investment decision.